Instituto de Investigación Sanitaria Galicia Sur (IISGS)
Centro de investigación
Institute Catalá Oncología
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Institute Catalá Oncología (18)
2024
-
Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study
Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 732-738
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis
Diabetologia, Vol. 66, Núm. 8, pp. 1481-1500
-
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
European Journal of Cancer, Vol. 182, pp. 3-14
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119
-
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial
Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661
-
Quality of life improvement in patients with bone metastases undergoing palliative radiotherapy
Reports of Practical Oncology and Radiotherapy, Vol. 27, Núm. 3, pp. 428-439
2021
-
10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer
International journal of radiation oncology, biology, physics, Vol. 111, Núm. 3, pp. S77
-
Erratum: Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (Nature communications (2021) 12 1 (1078))
Nature communications
-
Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial
Radiotherapy and Oncology, Vol. 160, pp. 115-119
2017
-
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
Nature Genetics, Vol. 49, Núm. 12, pp. 1767-1778
2016
-
Incidence and clearance of anal high-risk human papillomavirus in HIV-positive men who have sex with men: Estimates and risk factors
AIDS, Vol. 30, Núm. 1, pp. 37-44
-
Incidence of advanced neoplasia during surveillance in high- and intermediate-risk groups of the European colorectal cancer screening guidelines
Endoscopy, Vol. 48, Núm. 11, pp. 995-1002
-
Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial
International Journal of Radiation Oncology Biology Physics, Vol. 96, Núm. 2, pp. 341-348
2015
-
Incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: Multicenter prospective observational study
BMC Palliative Care, Vol. 14, Núm. 1
2012
-
Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer
Radiation Oncology, Vol. 7, Núm. 1
2011
-
Treatment of cancer with drugs: A controversy
Annals of Oncology
2008
-
Health-Related Quality of Life 2 Years After Treatment With Radical Prostatectomy, Prostate Brachytherapy, or External Beam Radiotherapy in Patients With Clinically Localized Prostate Cancer
International Journal of Radiation Oncology Biology Physics, Vol. 72, Núm. 2, pp. 421-432